Characterization of hepatobiliary transport systems of a novel α4β1/α4β7 dual antagonist, TR-14035

Pharmaceutical Research

Volumn 23, Issue 11, 2006, Pages 2646-2656

  Tsuda Tsukimoto, Minoru ^a   Maeda, Tomoji ^b   Iwanaga, Takashi ^b   Kume, Toshiyuki ^a   Tamai, Ikumi ^b  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

Genetic polymorphism; Hepatobiliary transport; MRP2; OATP

Indexed keywords

CARRIER PROTEIN; DIGOXIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; N (2,6 DICHLOROBENZOYL) 4 (2,6 DIMETHOXYPHENYL)PHENYLALANINE; ORGANIC ANION TRANSPORTER 1B3; ORGANIC ANION TRANSPORTER 2; PROTEIN INHIBITOR; TAUROCHOLIC ACID; TR 14035; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG TRANSPORT; EMBRYO; HEPATOBILIARY SYSTEM; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; KNOCKOUT MOUSE; LIVER CELL; MALE; MOUSE; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WILD TYPE; XENOPUS LAEVIS;

ANIMALS; BILE; BIOLOGICAL TRANSPORT; FEMALE; HEPATOCYTES; LIVER; MALE; MICE; MICE, KNOCKOUT; OOCYTES; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; P-GLYCOPROTEIN; PHENYLALANINE; POLYMORPHISM, SINGLE NUCLEOTIDE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33750629196     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9102-6     Document Type: Article

References (35)

1. C. Berlin, E. L. Berg, M. J. Briskin, D. P. Andrew, P. J. Kilshaw, B. Holzmann, I. L. Weissman, A. Hamann, and E. C. Butcher. α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 74:185-195 (1993).
2. C. Berlin, R. F. Bargatze, J. J. Campbell, U. H. von Andrian, M. C. Szabo, S. R. Hasslen, R. D. Nelson, E. L. Berg, S. L. Erlandsen, and E. C. Butcher. α4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell 80:413-422 (1995).
3. I. Sircar, K. S. Gudmundsson, R. Martin, J. Liang, S. Nomura, H. Jayakumar, B. R. Teegarden, D. M. Nowlin, P. M. Cardarelli, J. R. Mah, S. Connell, R. C. Griffith, and E. Lazarides. Synthesis and SAR of N-benzoyl-L-biphenylalanine derivatives: discovery of TR-14035, a dual α4β7/α4β1 integrin antagonist. Bioorg. Med. Chem. 10:2051-2066 (2002).
4. M. Tsuda-Tsukimoto, Y. Ogasawara, and T. Kume. Pharmacokinetics and metabolism of TR-14035, a novel antagonist of α4β1/α4β7 integrin mediated cell adhesion, in rat and dog. Xenobiotica 35:373-389 (2005).
5. M. Tsuda-Tsukimoto, Y. Ogasawara, and T. Kume. Role of human liver cytochrome P450 2C9 in the metabolism of a novel α4β1/α4β7 dual antagonist, TR-14035. Drug Metab. Pharmacokinet. 20:127-134 (2005).
6. B. Hagenbuch and P. J. Meier. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 447:653-665 (2004).
7. H. Koepsell and H. Endou. The SLC22 drug transporter family. Pflugers Arch. 447:666-676 (2004).
8. P. Chandra and K. L. Brouwer. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res. 21:719-735 (2004).
9. B. Sarkadi, C. Özvegy-Laczka, K. Német, and A. Váradi. ABCG2 - a transporter for all seasons. FEBS Lett. 567:116-120 (2004).
10. H. Baur, S. Kasperek, and E. Pfaff. Criteria of viability of isolated liver cells. Hoppe-Seyler Z. Physiol. Chem. 356:827-838 (1975).
11. Y. Shitara, T. Itoh, H. Sato, A. P. Li, and Y. Sugiyama. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J. Pharmacol. Exp. Ther. 304:610-616 (2003).
12. M. Schwenk. Transport systems of isolated hepatocytes: studies on the transport of biliary compounds. Arch. Toxicol. 44:113-126 (1980).
13. I. Tamai, T. Nozawa, M. Koshida, J. Nezu, Y. Sai, and A. Tsuji. Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm. Res. 18:1262-1269 (2001).
14. M. Tsuda, T. Sekine, M. Takeda, S. H. Cha, Y. Kanai, M. Kimura, and H. Endou. Transport of ochratoxin A by renal multispecific organic anion transporter 1. J. Pharmacol. Exp. Ther. 289:1301-1305 (1999).
15. M. Jordan, A. Schallhorn, and F. M. Wurm. Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res. 24:596-601 (1996).
16. I. Tamai, J. Nezu, H. Uchino, Y. Sai, A. Oku, M. Shimane, and A. Tsuji. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 273:251-260 (2000).
17. K. Yamaoka, Y. Tanigawara, T. Nakagawa, and T. Uno. A pharmacokinetics analysis program (MULTI) for microcomputer. J. Pharmacobio-Dyn. 4:879-885 (1981).
18. W. Lee, H. Glaeser, L. H. Smith, R. L. Roberts, G. W. Moeckel, G. Gervasini, B. F. Leake, and R. B. Kim. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J. Biol. Chem. 280:9610-9617 (2005).
19. M. Hirano, K. Maeda, H. Hayashi, H. Kusuhara, and Y. Sugiyama. Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J. Pharmacol. Exp. Ther. 314:876-882 (2005).
20. R. G. Tirona, B. F. Leake, G. Merino, and R. B. Kim. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J. Biol. Chem. 276:35669-35675 (2001).
21. T. Nozawa, M. Nakajima, I. Tamai, K. Noda, J. Nezu, Y. Sai, A. Tsuji, and T. Yokoi. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 302:804-813 (2002).
22. M. Iwai, H. Suzuki, I. Ieiri, K. Otsubo, and Y. Sugiyama. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 14:749-757 (2004).
23. T. Nozawa, S. Sugiura, M. Nakajima, A. Goto, T. Yokoi, J. Nezu, A. Tsuji, and I. Tamai. Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab. Dispos. 32:291-294 (2004).
24. T. Nozawa, H. Minami, S. Sugiura, A. Tsuji, and I. Tamai. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos. 33:434-439 (2005).
25. Y. Nishizato, I. Ieiri, H. Suzuki, M. Kimura, K. Kawabata, T. Hirota, H. Takane, S. Irie, H. Kusuhara, Y. Urasaki, A. Urae, S. Higuchi, K. Otsubo, and Y. Sugiyama. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73:554-565 (2003).
26. M. Niemi, E. Schaeffeler, T. Lang, M. F. Fromm, M. Neuvonen, C. Kyrklund, J. T. Backman, R. Kerb, M. Schwab, P. J. Neuvonen, M. Eichelbaum, and K. T. Kivistö. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14:429-440 (2004).
27. M. Niemi, K. T. Kivistö, U. Hofmann, M. Schwab, M. Eichelbaum, and M. F. Fromm. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br. J. Clin. Pharmacol. 59:602-604 (2005).
28. Y. Kameyama, K. Yamashita, K. Kobayashi, M. Hosokawa, and K. Chiba. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15 + C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics 15:513-522 (2005).
29. M. Niemi, J. T. Backman, L. I. Kajosaari, J. B. Leathart, M. Neuvonen, A. K. Daly, M. Eichelbaum, K. T. Kivistö, and P. J. Neuvonen. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther. 77:468-478 (2005).
30. Y. Shitara, H. Sato, and Y. Sugiyama. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol. 45:689-723 (2005).
31. S. G. Simonson, A. Raza, P. D. Martin, P. D. Mitchell, J. A. Jarcho, C. D. Brown, A. S. Windass, and D. W. Schneck. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharmacol. Ther. 76:167-177 (2004).
32. D. W. Schneck, B. K. Birmingham, J. A. Zalikowski, P. D. Mitchell, Y. Wang, P. D. Martin, K. C. Lasseter, C. D. Brown, A. S. Windass, and A. Raza. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. 75:455-463 (2004).
33. C. -Y. Wu and L. Z. Benet. Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine and GG918. Drug Metab. Dispos. 31:1292-1295 (2003).
34. Y. Y. Lau, C. -Y. Wu, H. Okochi, and L. Z. Benet. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J. Pharmacol. Exp. Ther. 308:1040-1045 (2004).
35. L. Liu and K. S. Pang. The roles of transporters and enzymes in hepatic drug processing. Drug Metab. Dispos. 33:1-9 (2005).